Your browser doesn't support javascript.
loading
Lamin A/C-Related Cardiac Disease: Late Onset With a Variable and Mild Phenotype in a Large Cohort of Patients With the Lamin A/C p.(Arg331Gln) Founder Mutation.
Hoorntje, Edgar T; Bollen, Ilse A; Barge-Schaapveld, Daniela Q; van Tienen, Florence H; Te Meerman, Gerard J; Jansweijer, Joeri A; van Essen, Anthonie J; Volders, Paul G; Constantinescu, Alina A; van den Akker, Peter C; van Spaendonck-Zwarts, Karin Y; Oldenburg, Rogier A; Marcelis, Carlo L; van der Smagt, Jasper J; Hennekam, Eric A; Vink, Aryan; Bootsma, Marianne; Aten, Emmelien; Wilde, Arthur A; van den Wijngaard, Arthur; Broers, Jos L; Jongbloed, Jan D; van der Velden, Jolanda; van den Berg, Maarten P; van Tintelen, J Peter.
Affiliation
  • Hoorntje ET; For the author affiliations, please see the Appendix.
  • Bollen IA; For the author affiliations, please see the Appendix.
  • Barge-Schaapveld DQ; For the author affiliations, please see the Appendix.
  • van Tienen FH; For the author affiliations, please see the Appendix.
  • Te Meerman GJ; For the author affiliations, please see the Appendix.
  • Jansweijer JA; For the author affiliations, please see the Appendix.
  • van Essen AJ; For the author affiliations, please see the Appendix.
  • Volders PG; For the author affiliations, please see the Appendix.
  • Constantinescu AA; For the author affiliations, please see the Appendix.
  • van den Akker PC; For the author affiliations, please see the Appendix.
  • van Spaendonck-Zwarts KY; For the author affiliations, please see the Appendix.
  • Oldenburg RA; For the author affiliations, please see the Appendix.
  • Marcelis CL; For the author affiliations, please see the Appendix.
  • van der Smagt JJ; For the author affiliations, please see the Appendix.
  • Hennekam EA; For the author affiliations, please see the Appendix.
  • Vink A; For the author affiliations, please see the Appendix.
  • Bootsma M; For the author affiliations, please see the Appendix.
  • Aten E; For the author affiliations, please see the Appendix.
  • Wilde AA; For the author affiliations, please see the Appendix.
  • van den Wijngaard A; For the author affiliations, please see the Appendix.
  • Broers JL; For the author affiliations, please see the Appendix.
  • Jongbloed JD; For the author affiliations, please see the Appendix.
  • van der Velden J; For the author affiliations, please see the Appendix.
  • van den Berg MP; For the author affiliations, please see the Appendix.
  • van Tintelen JP; For the author affiliations, please see the Appendix. p.vantintelen@amc.nl.
Circ Cardiovasc Genet ; 10(4)2017 Aug.
Article in En | MEDLINE | ID: mdl-28790152
BACKGROUND: Interpretation of missense variants can be especially difficult when the variant is also found in control populations. This is what we encountered for the LMNA c.992G>A (p.(Arg331Gln)) variant. Therefore, to evaluate the effect of this variant, we combined an evaluation of clinical data with functional experiments and morphological studies. METHODS AND RESULTS: Clinical data of 23 probands and 35 family members carrying this variant were retrospectively collected. A time-to-event analysis was performed to compare the course of the disease with carriers of other LMNA mutations. Myocardial biopsies were studied with electron microscopy and by measuring force development of the sarcomeres. Morphology of the nuclear envelope was assessed with immunofluorescence on cultured fibroblasts. The phenotype in probands and family members was characterized by atrioventricular conduction disturbances (61% and 44%, respectively), supraventricular arrhythmias (69% and 52%, respectively), and dilated cardiomyopathy (74% and 14%, respectively). LMNA p.(Arg331Gln) carriers had a significantly better outcome regarding the composite end point (malignant ventricular arrhythmias, end-stage heart failure, or death) compared with carriers of other pathogenic LMNA mutations. A shared haplotype of 1 Mb around LMNA suggested a common founder. The combined logarithm of the odds score was 3.46. Force development in membrane-permeabilized cardiomyocytes was reduced because of decreased myofibril density. Structural nuclear LMNA-associated envelope abnormalities, that is, blebs, were confirmed by electron microscopy and immunofluorescence microscopy. CONCLUSIONS: Clinical, morphological, functional, haplotype, and segregation data all indicate that LMNA p.(Arg331Gln) is a pathogenic founder mutation with a phenotype reminiscent of other LMNA mutations but with a more benign course.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lamin Type A / Heart Diseases Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Circ Cardiovasc Genet Journal subject: ANGIOLOGIA / CARDIOLOGIA / GENETICA MEDICA Year: 2017 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lamin Type A / Heart Diseases Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Circ Cardiovasc Genet Journal subject: ANGIOLOGIA / CARDIOLOGIA / GENETICA MEDICA Year: 2017 Document type: Article Country of publication: United States